Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 6/20 | 0.33 |
| ▸ | DRD4 | P21917 | 6/20 | 0.33 |
| ▸ | DRD3 | P35462 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429973 | 0.81 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6429972 | 0.81 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6402651 | 0.68 | — | — | |
| SCHEMBL3591487 | 0.67 | DRD2 (0.35) | DRD2DRD4DRD3 | |
| SCHEMBL6428600 | 0.63 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4680635 | 0.61 | IGF1R (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17499676 | 0.61 | ALDH1A1 (0.45) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL17499679 | 0.61 | ALDH1A1 (0.45) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL6429916 | 0.59 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14066488 | 0.57 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2005-01-20 | — | — | US | disclosed |
| EP-1437349-A1 | SUBSTITUTED ISOXAZOLES AND THE USE THEREOF AS ANTIBIOTICS | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014806-A1 | Substituted isoxazoles and their use as antibiotics | XDH, SCO2, HAX1 | PSEN1 3945/4885PSEN2 4522/4885APH1B 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.